脳画像および神経画像市場 - 世界の産業規模、シェア、動向、機会、予測：画像タイプ別、エンドユーザー別、地域別、競合別、2018年～2028年

世界の脳画像および神経画像市場は、2022年に111億2,000万米ドルと評価され、2028年までのCAGRは5.62%で、予測期間中に力強い成長が予測されています。

世界の脳画像および神経画像市場は、技術の進歩、神経科学研究の増加、人間の脳の複雑な仕組みに対する理解の深まりによって、著しい成長と進化を遂げています。この市場には、脳の構造と機能を可視化・分析するために設計された幅広い画像技術やテクノロジーが含まれています。磁気共鳴画像法（MRI）、コンピュータ断層撮影法（CT）、陽電子放出断層撮影法（PET）、単一光子放出コンピュータ断層撮影法（SPECT）、機能的MRI（fMRI）などは、この市場の拡大に貢献している主要なモダリティの一つです。

世界の脳画像および神経画像市場の成長の原動力の1つは、アルツハイマー病、パーキンソン病、さまざまな精神疾患などの神経疾患や症状の有病率の上昇です。世界の人口が高齢化し、これらの疾患の発生率が高まるにつれて、早期発見と効果的な治療計画のための高度な診断ツールや技術に対する需要が増加しています。ニューロイメージングは、これらの疾患に関連する脳の構造的・機能的変化に関する洞察を提供し、臨床医がより多くの情報に基づいた判断を下せるようにする上で重要な役割を果たしています。

さらに、現在進行中の研究開発活動は、脳画像技術の能力を絶えず向上させています。高解像度イメージング、機能的結合マッピング、画像解析のための人工知能の統合などの革新は、脳イメージングの診断および研究用途を拡大しています。これらの進歩は診断の精度を向上させるだけでなく、脳機能と神経学的プロセスの理解にも貢献しています。

市場促進要因

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の脳画像および神経画像市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 画像タイプ別（機能的磁気共鳴画像法（fMRI）、コンピュータ断層撮影法（CT）、陽電子放射断層撮影法（PET）、脳波法（EEG）、脳磁図法（MEG）、近赤外分光法（NIRS））
  • エンドユーザー別（病院・クリニック、外来手術センター、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 画像タイプ別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋の脳画像および神経画像市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 画像タイプ別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の脳画像および神経画像市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 画像タイプ別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の脳画像および神経画像市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 画像タイプ別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の脳画像および神経画像市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 画像タイプ別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの脳画像および神経画像市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 画像タイプ別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の脳画像および神経画像市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Varian Medical Systems
  • 事業概要
  • 企業概要
  • 製品・サービス
  • 現在の生産能力分析
  • 財務状況
  • 最近の動向
  • SWOT分析
• General Electric Company
• Siemens AG
• Philips Healthcare
• Toshiba Medical Systems
• Hitachi Medical Systems
• Esaote SpA
• Sanrad Medical Systems Pvt. Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Brain Imaging and Neuroimaging Market has valued at USD 11.12 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.62% through 2028. The Global Brain Imaging and Neuroimaging Market is undergoing significant growth and evolution, fueled by advancements in technology, increased research in neuroscience, and a growing understanding of the intricate workings of the human brain. This market encompasses a broad spectrum of imaging techniques and technologies designed to visualize and analyze the structure and function of the brain. Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and functional MRI (fMRI) are among the key modalities contributing to the expansion of this market.

One of the driving forces behind the growth of the global brain imaging and neuroimaging market is the rising prevalence of neurological disorders and conditions, including Alzheimer's disease, Parkinson's disease, and various psychiatric disorders. As the global population ages and the incidence of these conditions increases, the demand for advanced diagnostic tools and techniques for early detection and effective treatment planning is on the rise. Neuroimaging plays a crucial role in providing insights into the structural and functional changes in the brain associated with these disorders, enabling clinicians to make more informed decisions.

Moreover, ongoing research and development activities are continually enhancing the capabilities of brain imaging technologies. Innovations such as high-resolution imaging, functional connectivity mapping, and the integration of artificial intelligence for image analysis are expanding the diagnostic and research applications of brain imaging. These advancements not only improve the accuracy of diagnosis but also contribute to our understanding of brain function and neurological processes.

Key Market Drivers

Technological Advancements

Technological advancements stand as a driving force behind the robust growth of the Global Brain Imaging and Neuroimaging Market, ushering in a new era of precision, efficiency, and expanded capabilities in imaging modalities. Notable progress in Magnetic Resonance Imaging (MRI) has been instrumental in achieving higher resolutions and clearer insights into the intricacies of brain structures. Advanced MRI techniques, such as functional MRI (fMRI) and diffusion tensor imaging (DTI), enable real-time mapping of brain functions and intricate connectivity patterns. Computed Tomography (CT) has evolved with the introduction of higher-slice machines, enhancing imaging speed and resolution. Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) benefit from innovations in radiotracer development, enabling more precise detection of metabolic and functional changes within the brain.

Artificial Intelligence (AI) integration represents a transformative leap in the field, optimizing the interpretation and analysis of complex imaging data. AI algorithms are adept at recognizing subtle patterns, anomalies, and correlations within brain images, facilitating faster and more accurate diagnoses. Machine learning models are being employed to predict disease progression, personalize treatment plans, and even identify early signs of neurological disorders before clinical symptoms manifest. These advancements not only enhance diagnostic accuracy but also streamline workflows, reducing the time required for analysis and interpretation.

Moreover, neuroimaging technologies are witnessing a convergence with other cutting-edge technologies. Augmented and virtual reality are being incorporated into surgical planning and training, providing surgeons with immersive, 3D visualizations of the brain for more precise interventions. Furthermore, advancements in imaging hardware, such as the development of more sensitive detectors and higher-field-strength magnets for MRI, contribute to improved image quality and diagnostic accuracy.

The growing emphasis on multimodal imaging is another facet of technological progression in the field. Combining different imaging modalities, such as PET-MRI and SPECT-CT, offers a comprehensive view of both anatomical and functional aspects, providing a more holistic understanding of neurological conditions. This integration enhances diagnostic capabilities and aids in the development of targeted treatment strategies.

Rising Prevalence of Neurological Disorders

The escalating prevalence of neurological disorders stands as a pivotal driver propelling the growth of the Global Brain Imaging and Neuroimaging Market. Across the globe, conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and various psychiatric disorders are on the rise, creating an urgent need for advanced diagnostic tools and precise imaging technologies. As populations age and life expectancies increase, the incidence of these neurological disorders has become more pronounced, contributing to an expanding patient pool. The imperative for early detection and intervention in neurological diseases underscores the significance of brain imaging and neuroimaging techniques, which offer invaluable insights into the structural and functional changes occurring in the brain. These modalities not only aid in accurate diagnosis but also facilitate the monitoring of disease progression, enabling healthcare professionals to tailor treatment plans for optimal patient outcomes.

The increasing burden of neurological disorders places a significant demand on healthcare systems globally, prompting a heightened focus on innovative diagnostic solutions. Brain imaging technologies play a pivotal role in meeting this demand by providing non-invasive and comprehensive assessments of the brain's condition. The ability to visualize and understand the intricate details of neural structures and functions is essential for clinicians to make informed decisions regarding treatment strategies. Moreover, the rising awareness among both healthcare professionals and the general population about the importance of early diagnosis and intervention in neurological conditions further fuels the adoption of brain imaging technologies.

The neuroimaging market's response to the rising prevalence of neurological disorders goes beyond diagnostics; it extends to pharmaceutical development and clinical research. Drug discovery and development for neurological conditions require a deep understanding of disease mechanisms, and neuroimaging techniques serve as invaluable tools for assessing treatment efficacy in clinical trials. As the pharmaceutical industry endeavors to develop targeted therapies for various neurological disorders, the demand for advanced imaging technologies continues to escalate.

Expanding Applications in Drug Development

The Global Brain Imaging and Neuroimaging Market are experiencing a significant boost in growth, propelled by the expanding applications of these technologies in drug development. As the pharmaceutical industry strives to address the complexities of neurological disorders, brain imaging has emerged as a crucial tool in the development and evaluation of novel therapeutic interventions. Neuroimaging techniques play a pivotal role in preclinical research and clinical trials, providing valuable insights into the effects of potential drug candidates on the structure and function of the brain.

In preclinical stages, neuroimaging enables researchers to non-invasively visualize and quantify the impact of experimental drugs on brain structures and functions in animal models. This aids in the early identification of promising candidates and facilitates more informed decisions on which compounds to advance to clinical trials. The ability to assess the pharmacokinetics and pharmacodynamics of drugs in preclinical phases contributes to the efficiency of drug development pipelines, potentially reducing the time and resources required for bringing new treatments to market.

In clinical trials, neuroimaging serves as a crucial endpoint for evaluating the efficacy and safety of therapeutic interventions. Functional MRI (fMRI), Positron Emission Tomography (PET), and other imaging modalities allow researchers to monitor changes in brain activity, connectivity, and metabolic processes in response to treatment. These biomarkers provide objective and quantitative measures of treatment response, aiding in the determination of a drug's effectiveness and its impact on disease progression.

The integration of neuroimaging into drug development also supports the emerging trend of precision medicine. By leveraging imaging data, researchers can identify subpopulations of patients who are more likely to respond positively to a particular treatment. This personalized approach enhances the success rates of clinical trials and contributes to the development of targeted therapies tailored to the unique characteristics of individual patients.

Furthermore, regulatory agencies increasingly recognize the importance of neuroimaging data in the drug approval process. The inclusion of imaging biomarkers as surrogate endpoints in clinical trials enhances the regulatory decision-making process, expediting the approval of drugs that demonstrate positive effects on the brain. This recognition further incentivizes pharmaceutical companies to incorporate neuroimaging endpoints in their development programs.

Key Market Challenges

Regulatory Complexities

The Global Brain Imaging and Neuroimaging Market, while holding immense potential for revolutionizing healthcare accessibility, encounters a significant impediment in the form of regulatory complexities. The diverse and often stringent regulatory frameworks across different regions and countries present a formidable challenge to the streamlined deployment and operation of Brain Imaging and Neuroimaging on a global scale.

One of the primary regulatory challenges faced by the Global Brain Imaging and Neuroimaging Market lies in the varied licensing and certification requirements for healthcare services in different jurisdictions. Each country or region may have its own set of rules governing the establishment, operation, and scope of services provided by healthcare facilities, including mobile clinics. Navigating this intricate web of regulations demands substantial resources, time, and expertise, creating hurdles for the standardized and efficient deployment of Brain Imaging and Neuroimaging worldwide.

Furthermore, the lack of harmonization in regulatory standards poses a barrier to achieving consistency in the quality of healthcare services offered by mobile clinics. The absence of a standardized regulatory framework can lead to disparities in the types of services Brain Imaging and Neuroimaging can provide, hindering their ability to offer a comprehensive range of medical interventions across diverse geographies.

In some instances, the regulatory landscape may not be explicitly tailored to address the unique characteristics of mobile healthcare units. Outdated or inflexible regulations may fail to accommodate the dynamic and adaptive nature of mobile clinics, limiting their ability to respond swiftly to emerging healthcare needs or shifting demographics in different regions..

Sustainable Funding Models

Global Brain Imaging and Neuroimaging Market. Unlike traditional healthcare facilities with fixed infrastructure, Brain Imaging and Neuroimaging operate in dynamic and often resource-constrained environments, relying heavily on secure and sustainable funding to maintain their critical services. The challenge lies in developing financial models that ensure the continued operation and expansion of Brain Imaging and Neuroimaging while addressing the unique financial considerations inherent in their mobility and adaptability.

One of the primary hurdles faced by the Global Brain Imaging and Neuroimaging Market is the reliance on external funding sources, such as grants, donations, or subsidies. While these sources can kickstart mobile clinic initiatives and support specific projects, they often lack the long-term sustainability required for ongoing operations. As a result, Brain Imaging and Neuroimaging may face uncertainties in funding availability, hindering their ability to plan and execute healthcare interventions consistently.

The unpredictability of funding sources can be exacerbated by competing priorities in the realm of global health. Humanitarian crises, natural disasters, and other emergencies often divert attention and resources away from sustained funding for mobile clinics. This volatility underscores the need for more stable and resilient funding models that can weather unforeseen challenges and ensure the continuous operation of mobile clinics.

Innovative financing strategies are crucial to overcoming this challenge. Exploring public-private partnerships, where governments, non-profit organizations, and private sector entities collaborate, can create a more diverse and robust funding base. Governments can play a pivotal role by incorporating Brain Imaging and Neuroimaging into their healthcare budgets and exploring ways to incentivize private sector involvement.

Key Market Trends

Growing Emphasis on Early Diagnosis and Treatment

In recent years, there has been a remarkable shift in the healthcare landscape, with a growing emphasis on early diagnosis and treatment of neurological disorders. This paradigm shift has not only transformed patient outcomes but has also acted as a catalyst for the expansion of the global brain imaging and neuroimaging market. The recognition of the critical role played by early detection in managing conditions such as Alzheimer's disease, Parkinson's disease, and various psychiatric disorders has spurred increased investment in advanced imaging technologies.

The global brain imaging and neuroimaging market has witnessed a surge in demand for cutting-edge diagnostic tools that enable healthcare professionals to detect abnormalities in the brain at an early stage. Advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) have become indispensable in providing detailed insights into the structure and function of the brain. These technologies allow for the identification of subtle changes in the brain's anatomy and physiology, facilitating early intervention and personalized treatment plans.

Furthermore, the integration of artificial intelligence (AI) and machine learning algorithms into neuroimaging has significantly enhanced diagnostic accuracy and efficiency. These technologies enable the extraction of meaningful patterns and biomarkers from complex neuroimaging data, aiding in the early identification of neurological disorders. The synergy between technological advancements and clinical research has propelled the global brain imaging market to new heights, fostering a more comprehensive understanding of the intricate workings of the brain.

Governments, healthcare institutions, and industry stakeholders worldwide are recognizing the importance of investing in neuroimaging research and infrastructure. Initiatives aimed at promoting awareness, research collaborations, and the development of innovative neuroimaging techniques are on the rise. Additionally, the growing prevalence of neurological disorders, coupled with an aging population, has intensified the urgency for early diagnosis and intervention, further propelling the market forward.

Integration of Artificial Intelligence (AI)

The integration of Artificial Intelligence (AI) is playing a pivotal role in propelling the Global Brain Imaging and Neuroimaging Market to unprecedented heights. This marriage of cutting-edge technology with neuroscience is revolutionizing the field, offering transformative solutions that significantly enhance diagnostic capabilities and research endeavors. AI algorithms, driven by machine learning and deep learning techniques, are adept at analyzing vast and complex datasets generated by brain imaging technologies. In Magnetic Resonance Imaging (MRI), AI is optimizing image reconstruction, enabling faster scans with improved resolution and clarity. In Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT), AI is revolutionizing image interpretation, providing more accurate and quantitative assessments of metabolic and functional changes in the brain.

The efficiency gains realized through AI integration extend beyond image analysis. AI is reshaping the landscape of neuroimaging research and drug development. It facilitates the identification of subtle patterns and biomarkers associated with neurological disorders, aiding researchers in unraveling the complexities of brain diseases. Moreover, AI-driven predictive modeling is enabling early risk assessment for the development of neurological conditions, paving the way for proactive healthcare interventions. In clinical trials, AI contributes to the optimization of participant selection, more accurate monitoring of treatment responses, and streamlined data analysis, thereby expediting the development of novel therapies.

The significance of AI in the neuroimaging market is further underscored by its ability to augment precision medicine. Tailoring treatments to individual patient profiles is becoming increasingly feasible with AI-driven insights derived from neuroimaging data. This personalized approach enhances treatment efficacy, minimizes adverse effects, and represents a paradigm shift towards more targeted and patient-centric healthcare.

Segmental Insights

Imaging Type Insights

Based on the Imaging Type, Functional Magnetic Resonance Imaging (fMRI) emerged as the dominant segment in the global market for Global Hematology Brain Imaging and Neuroimaging in 2022. fMRI provides a non-invasive means to visualize and map brain activity by measuring changes in blood flow and oxygenation. This allows researchers and clinicians to examine the functional aspects of the brain, such as neural responses to stimuli or tasks. The ability to study brain function in real-time makes fMRI an invaluable tool for both research and clinical applications. fMRI offers high spatial resolution, allowing for detailed localization of brain activity. This capability is crucial for identifying specific regions of interest and understanding the intricate networks within the brain. The spatial precision of fMRI is particularly advantageous in studying localized brain functions, such as those associated with language, motor skills, and sensory processing.

End User Insights

Based on the End User, Hospitals and clinics emerged as the dominant segment in the global market for Global Brain Imaging and Neuroimaging Market in 2022. hospitals serve as comprehensive healthcare facilities, offering a wide range of medical services, including diagnostic imaging. The complex nature of neurological disorders often requires a multidisciplinary approach to diagnosis and treatment, making hospitals the primary hub for the integration of neuroimaging into patient care. Additionally, hospitals are equipped to handle a diverse patient population, including those with acute or severe neurological conditions requiring immediate attention.

Regional Insights

North America emerged as the dominant player in the Global Brain Imaging and Neuroimaging Market in 2022, holding the largest market share. North America has a robust and advanced healthcare infrastructure, particularly in the United States and Canada. These countries are at the forefront of adopting and integrating innovative medical technologies, including state-of-the-art brain imaging and neuroimaging equipment. The availability of cutting-edge imaging modalities in major healthcare facilities across North America positions the region as a leader in the global market. significant investments in research and development within the healthcare sector contribute to the dominance of North America in the neuroimaging market. The region is home to numerous research institutions, academic centers, and pharmaceutical companies that actively engage in neuroscience research and clinical trials. This emphasis on research fosters the development and adoption of advanced brain imaging technologies, further solidifying North America's position in the market.

Key Market Players

Varian Medical Systems

General Electric Company

Siemens AG

Philips Healthcare

Toshiba Medical Systems

Hitachi Medical Systems

Esaote SpA

Sanrad Medical Systems Pvt. Ltd

Report Scope:

In this report, the Global Brain Imaging and Neuroimaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Brain Imaging and Neuroimaging Market, By Imaging Type:

• Functional Magnetic Resonance Imaging (fMRI)
• Computed Tomography (CT)
• Positron Emission Tomography (PET)
• Electroencephalography (EEG)
• Magnetoencephalography (MEG)
• Near Infrared Spectroscopy (NIRS)

Global Brain Imaging and Neuroimaging Market, By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Brain Imaging and Neuroimaging Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Brain Imaging and Neuroimaging Market.

Available Customizations:

• Global Brain Imaging and Neuroimaging Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Brain Imaging and Neuroimaging Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Imaging Type (Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magnetoencephalography (MEG), Near Infrared Spectroscopy (NIRS))
  • 4.2.2. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Imaging Type
  • 4.3.2. By End User
  • 4.3.3. By Region

5. Asia Pacific Brain Imaging and Neuroimaging Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Imaging Type
  • 5.2.2. By End User
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Brain Imaging and Neuroimaging Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Imaging Type
      • 5.3.1.2.2. By End User
  • 5.3.2. India Brain Imaging and Neuroimaging Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Imaging Type
      • 5.3.2.2.2. By End User
  • 5.3.3. Australia Brain Imaging and Neuroimaging Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Imaging Type
      • 5.3.3.2.2. By End User
  • 5.3.4. Japan Brain Imaging and Neuroimaging Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Imaging Type
      • 5.3.4.2.2. By End User
  • 5.3.5. South Korea Brain Imaging and Neuroimaging Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Imaging Type
      • 5.3.5.2.2. By End User

6. Europe Brain Imaging and Neuroimaging Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Imaging Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Brain Imaging and Neuroimaging Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Imaging Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Germany Brain Imaging and Neuroimaging Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Imaging Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Spain Brain Imaging and Neuroimaging Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Imaging Type
      • 6.3.3.2.2. By End User
  • 6.3.4. Italy Brain Imaging and Neuroimaging Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Imaging Type
      • 6.3.4.2.2. By End User
  • 6.3.5. United Kingdom Brain Imaging and Neuroimaging Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Imaging Type
      • 6.3.5.2.2. By End User

7. North America Brain Imaging and Neuroimaging Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Imaging Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Brain Imaging and Neuroimaging Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Imaging Type
      • 7.3.1.2.2. By End User
  • 7.3.2. Mexico Brain Imaging and Neuroimaging Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Imaging Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Canada Brain Imaging and Neuroimaging Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Imaging Type
      • 7.3.3.2.2. By End User

8. South America Brain Imaging and Neuroimaging Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Imaging Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Brain Imaging and Neuroimaging Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Imaging Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Argentina Brain Imaging and Neuroimaging Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Imaging Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Colombia Brain Imaging and Neuroimaging Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Imaging Type
      • 8.3.3.2.2. By End User

9. Middle East and Africa Brain Imaging and Neuroimaging Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Imaging Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Brain Imaging and Neuroimaging Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Imaging Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Saudi Arabia Brain Imaging and Neuroimaging Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Imaging Type
      • 9.3.2.2.2. By End User
  • 9.3.3. UAE Brain Imaging and Neuroimaging Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Imaging Type
      • 9.3.3.2.2. By End User
  • 9.3.4. Egypt Brain Imaging and Neuroimaging Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Imaging Type
      • 9.3.4.2.2. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Brain Imaging and Neuroimaging Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Varian Medical Systems
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. General Electric Company
• 14.3. Siemens AG
• 14.4. Philips Healthcare
• 14.5. Toshiba Medical Systems
• 14.6. Hitachi Medical Systems
• 14.7. Esaote SpA
• 14.8. Sanrad Medical Systems Pvt. Ltd

15. Strategic Recommendations

16. About Us & Disclaimer